News Filter by: Industry Team AutomotiveEnergyFood & BeverageHealth Care Hospitality & LeisureLife SciencesManufacturingMaritime RetailSportsTechnology Practice Area Corporate All CorporateEmployee Benefits & Executive CompensationEnvironmentalEstates & TrustsFinanceInsurance Private Equity & Venture CapitalReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactions Government Solutions All Government SolutionsExport Controls & National SecurityFDA RegulatoryFederal & State Energy RegulatoryFreight & Commuter RailGovernment Procurement Immigration, Nationality & Consular LawNHTSA & Motor Vehicle SafetyPolitical LawPublic PolicyState Attorneys GeneralStrategic Communications Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalCybersecurityElectronicsGreen Energy TechnologiesIP Asset Management IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPTAB TrialsTechnology Transactions & OutsourcingTrademark, Copyright & Advertising Counseling International All InternationalChinaEurope IsraelJapanMexico Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Law, Finance & Class ActionDistribution & Franchise Energy LitigationGovernment Enforcement Defense & InvestigationsInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Office AustinBostonChicagoDallasDenverDetroitHoustonJacksonville Los AngelesMadisonMexico CityMiamiMilwaukeeNew YorkOrlandoSacramento San DiegoSan FranciscoSilicon ValleyTallahasseeTampaTokyoWashington, D.C. Topic Big DataCuba Foreign Corrupt Practices Act (FCPA)Health Care Reform Telemedicine In the News Press Releases Media Contact Jill Chanen Public Relations Manager jchanen foley.com 312.832.4745 123next 18 April 2019 Rosen Comments on Korean Pharma Companies Doing Business in the U.S. –Korea Biomedical Review Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America. 09 March 2019 Rosen Comments on FDA Commissioner’s Tenure –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “Stakeholders anxious about FDA losing momentum after Gottlieb exits,” about the legacy of Food and Drug Administration Commissioner Dr. Scott Gottlieb, who announced his resignation last week. 20 February 2019 Faget Comments on Likely Effects of HHS Proposal to Curb Rebates –BioPharm Insight Special Counsel Kyle Faget is quoted in a BioPharm Insight article, “Biosimilars, diabetes and HCV drug uptake expected to spike with HHS changes restricting safe harbor protection for PBMs and drug manufacturers, experts say,” about the expected impact of a new U.S. Department of Health and Human Services proposal to exclude rebates on prescription drugs from safe harbor protection under the anti-kickback statute. 15 February 2019 Beaver Discusses Advocate's Call for Requiring Food Companies to Identify Retailers in Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Advocate: FDA Should Make Food Companies List Retailers in Recalls," about a food safety advocate's demand that food companies be required to disclose the names of retailers involved in recalls. 11 January 2019 Beaver Comments on Food Safety Threat During Government Shutdown –Law360 Partner Nathan Beaver was quoted in a Law360 article, “Government Shutdown Stretches FDA Food Safety Thin,” about the threat to food safety posed by the partial shutdown of the federal government. 08 January 2019 Faget Comments on Updates to FDA’s Pre-Cert Program –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, “FDA looks to De Novo pathway model as it unveils updates to Pre-Cert program,” about the FDA’s unveiling of new updates to its Digital Health Precertification (Pre-Cert) program. 19 December 2018 Geilfuss, Faget Comment on Implications of Possible ACA Ruling –Modern Healthcare Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional. 04 December 2018 Rosen Comments on Report That Found Flaws in FDA Drug Approval Process –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, "Federal investigation finds holes in orphan drug approval process," about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration's process for approving so-called orphan drugs. 19 November 2018 Faget Comments on FDA Proposal to Streamline Premarket Review Submissions –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review. 18 October 2018 Beaver Comments on FDA Guidance Over Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls," about the FDA's recent guidance on disclosing food retailer information during certain recalls. 123next Search News Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared
18 April 2019 Rosen Comments on Korean Pharma Companies Doing Business in the U.S. –Korea Biomedical Review Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America.
09 March 2019 Rosen Comments on FDA Commissioner’s Tenure –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “Stakeholders anxious about FDA losing momentum after Gottlieb exits,” about the legacy of Food and Drug Administration Commissioner Dr. Scott Gottlieb, who announced his resignation last week.
20 February 2019 Faget Comments on Likely Effects of HHS Proposal to Curb Rebates –BioPharm Insight Special Counsel Kyle Faget is quoted in a BioPharm Insight article, “Biosimilars, diabetes and HCV drug uptake expected to spike with HHS changes restricting safe harbor protection for PBMs and drug manufacturers, experts say,” about the expected impact of a new U.S. Department of Health and Human Services proposal to exclude rebates on prescription drugs from safe harbor protection under the anti-kickback statute.
15 February 2019 Beaver Discusses Advocate's Call for Requiring Food Companies to Identify Retailers in Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Advocate: FDA Should Make Food Companies List Retailers in Recalls," about a food safety advocate's demand that food companies be required to disclose the names of retailers involved in recalls.
11 January 2019 Beaver Comments on Food Safety Threat During Government Shutdown –Law360 Partner Nathan Beaver was quoted in a Law360 article, “Government Shutdown Stretches FDA Food Safety Thin,” about the threat to food safety posed by the partial shutdown of the federal government.
08 January 2019 Faget Comments on Updates to FDA’s Pre-Cert Program –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, “FDA looks to De Novo pathway model as it unveils updates to Pre-Cert program,” about the FDA’s unveiling of new updates to its Digital Health Precertification (Pre-Cert) program.
19 December 2018 Geilfuss, Faget Comment on Implications of Possible ACA Ruling –Modern Healthcare Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
04 December 2018 Rosen Comments on Report That Found Flaws in FDA Drug Approval Process –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, "Federal investigation finds holes in orphan drug approval process," about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration's process for approving so-called orphan drugs.
19 November 2018 Faget Comments on FDA Proposal to Streamline Premarket Review Submissions –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review.
18 October 2018 Beaver Comments on FDA Guidance Over Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls," about the FDA's recent guidance on disclosing food retailer information during certain recalls.